Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib vs Bevacizumab with FOLFIRI in 2nd-line mCRC
NCT03271255Phase 2Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- May 2018
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Progression-free Survival at 2 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03271255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271255.